Advocacy Campaigns

Current advocacy campaigns

Have your say on PBS listings for IBD Medications

The Pharmaceutical Benefits Advisory Committee (PBAC) is seeking consumer feedback on IBD medications which are being considered for PBS listing. If you would like to provide feedback on vedolizumab (Entyvio®) for pouchitis, another adalimumab biosimilar (Hyrimoz®) or methotrexate (Methoblastin®) then send us an email about what difference it has made/would make to your life to [email protected]. We will then forward all comments consolidated to PBAC. The closing date for comments to CCA is 27 May 2024.

Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name®, Sponsor, new listing/change to listing)	Drug Type and Use (What is the drug used to treat?)	Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.)
ADALIMUMAB Injection 20 mg in 0.2 mL pre-filled syringe Injection 40 mg in 0.4 mL pre-filled syringe Injection 40 mg in 0.4 mL pre-filled pen Injection 80 mg 0.8 mL pre-filled syringe Injection 80 mg in 0.8 mL pre-filled pen Hyrimoz® SANDOZ PTY LTD (New PBS listing)	Severe Crohn disease (CD) Moderate to severe ulcerative colitis (UC) Severe active juvenile idiopathic arthritis (JIA) Complex refractory fistulising Crohn disease (CD) Severe active rheumatoid arthritis (RA) Severe psoriatic arthritis (PsA) Ankylosing spondylitis (AS) Severe chronic plaque psoriasis (CPP) Moderate to severe hidradenitis suppurativa (HS)	To request General Schedule and Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listings for initial treatment and Authority Required (STREAMLINED) listings for subsequent continuing treatment of new forms of an existing biosimilar under the same conditions as the currently listed forms and strengths as its reference biologic.
METHOTREXATE Tablet 2.5 mg (as sodium) Tablet 10 mg (as sodium) Methoblastin® PFIZER AUSTRALIA PTY LTD (New PBS listing)	Chemotherapy and inflammatory conditions	To request a General Schedule unrestricted listing of new forms and to request listing of a new pack size.
VEDOLIZUMAB Powder for injection 300 mg Entyvio® TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD. (Change to existing listing)	Chronic pouchitis	To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for initial treatment and an Authority Required (Telephone/Online) listing for continuing treatment of chronic pouchitis.